GLP-1 maintenance phase: what the science says about staying off

What did @branneisha actually say?

Branneisha has been in what she calls "maintenance" since October, holding a 85-pound weight loss by staying on a GLP-1 medication at a reduced dose. She describes maintenance as deeply personal, saying some people dose every 10 days, every two weeks, or once a month. Her own preference is weekly injections at a lower dose, specifically stepping down from 12.5 to 10, and potentially to 7.5 if she keeps losing. She also says she takes the medication long-term for PCOS symptom management and cites "anti-inflammatory" and "hormone regulation" benefits. She is clear that she plans to stay on it indefinitely and that getting off is a valid personal choice, not a medical recommendation.

The tone here is personal testimony, not medical advice, and she credits her doctor throughout. That framing matters when evaluating what she actually claims.

Does the science back this up?

Mostly yes, with some important nuances. The core claim, that people regain weight after stopping GLP-1 medications, is well-supported. The harder question is whether indefinite low-dose maintenance is clinically validated, and the honest answer is: not yet, at least not formally.

The STEP 4 trial (Rubino et al., 2021, JAMA) showed that participants who discontinued semaglutide after 20 weeks regained roughly two-thirds of their lost weight within a year. That data supports the intuition behind staying on the medication. However, STEP 4 did not test low-dose maintenance protocols. The trials we have use fixed doses on fixed schedules.

On PCOS, there is legitimate emerging evidence. A 2023 meta-analysis (Guo et al., Frontiers in Endocrinology) found GLP-1 receptor agonists improved menstrual regularity, androgen levels, and insulin resistance in women with PCOS. So the PCOS rationale she describes is not invented, though "hormone regulation" is a loose way to describe what the evidence actually shows.

The anti-inflammatory claim has support in mechanistic and observational research, but no large RCTs have been conducted specifically on low-dose GLP-1 use for inflammation management outside metabolic disease contexts.

What did they get wrong (or right)?

She got several things right. Weight regain after stopping is real. Long-term medication use for chronic conditions is a legitimate clinical strategy. Her PCOS rationale is grounded in real science. And her insistence that dosing decisions belong to "you and your doctor" is exactly the right framing.

Where she gets loose is the dosing flexibility language. Describing intervals of "every 10 days, every nine days, every two weeks, once a month" as normal maintenance variation glosses over a real problem: most GLP-1 medications are not pharmacologically tested at those irregular schedules. Semaglutide's half-life is roughly one week, which is why weekly dosing exists. Stretch that interval and you are not just tapering, you are introducing unpredictable trough levels. That is not inherently dangerous, but presenting it casually as a known maintenance strategy overstates what the evidence supports.

She also describes stepping down through dose increments as a self-guided titration process. That is a clinical decision, not a personal preference experiment. To her credit, she implies her doctor is involved, but that connection gets blurry in the narrative.

What should you actually know?

If you are thinking about GLP-1 maintenance, here is what the evidence actually tells you. First, stopping the medication typically means significant weight regain, and that is a physiological reality, not a personal failure. Second, long-term use appears safe based on current data, including the SELECT trial (Lincoff et al., 2023, New England Journal of Medicine), which tracked cardiovascular outcomes over multiple years.

Third, maintenance dosing is genuinely understudied. Clinicians are figuring this out in real time. Some prescribers do taper patients to lower doses or extended intervals, but there is no consensus protocol. If your provider offers a maintenance plan, ask what evidence base they are using.

Fourth, the PCOS benefit is real but condition-specific. GLP-1s are not approved for PCOS treatment, and results vary significantly based on baseline insulin resistance and other factors. This is a conversation for an endocrinologist or reproductive endocrinologist, not a TikTok comment section.

Finally, "I'm on this for life" is a valid personal conclusion, but it should come after a clinical conversation about your specific risk profile, not as a default assumption.